QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:EXASEXACT Sciences Stock Price, Forecast & News

$85.33
-1.87 (-2.14 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$84.88
Now: $85.33
$87.36
50-Day Range
$80.96
MA: $91.15
$100.36
52-Week Range
$35.25
Now: $85.33
$123.31
Volume652,622 shs
Average Volume1.97 million shs
Market Capitalization$12.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.9
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Read More
EXACT Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-535-8815

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$876.29 million
Book Value$17.62 per share

Profitability

Net Income$-83,990,000.00

Miscellaneous

Employees4,110
Market Cap$12.81 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$85.33
-1.87 (-2.14 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

How has EXACT Sciences' stock been impacted by Coronavirus (COVID-19)?

EXACT Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EXAS stock has increased by 47.6% and is now trading at $85.33.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of EXACT Sciences?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for EXACT Sciences
.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for EXACT Sciences
.

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings data on Thursday, July, 30th. The medical research company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.04. The medical research company earned $268.87 million during the quarter, compared to analyst estimates of $229.62 million. EXACT Sciences had a negative return on equity of 13.32% and a negative net margin of 13.65%.
View EXACT Sciences' earnings history
.

What price target have analysts set for EXAS?

15 brokerages have issued twelve-month target prices for EXACT Sciences' shares. Their forecasts range from $70.00 to $127.00. On average, they anticipate EXACT Sciences' share price to reach $106.43 in the next year. This suggests a possible upside of 24.7% from the stock's current price.
View analysts' price targets for EXACT Sciences
.

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:
  • 1. According to Zacks Investment Research, "Exact Sciences’ higher Cologuard volumes boosted its legacy Screening business. Gross margin expansion and an overall strong solvency are also encouraging. Continued strong demand for tests needed for cancer treatment mitigated the overall revenue impact. Delivery of critical care and accelerated launch of its telehealth site to lessen direct interactions with health care providers during the pandemic are noteworthy. Its performance in the first quarter of 2020 was robust with better-than-expected revenues, thanks to the Genomic Health acquisition. Yet, fewer patient visits and surgery deferrals due to COVID-19 are concerning. Sole reliance on Cologuard and competitive headwinds are other major downsides. Rising expenses and operating loss also do not bode well. Overall, Exact Sciences has underperformed its industry over the past six months." (7/13/2020)
  • 2. Canaccord Genuity analysts commented, "We are buyers of EXAS following the unusual 10% weakness in shares today, which we believe were part of the overall selloff today in diagnostics (and software stocks), where much of the alpha in the overall stock market has come from; and what we believe is likely certain funds pressuring EXAS following a cost effectiveness study published last week, but got a lot more attention today on the Street. We believe this is a buy-on- weakness opportunity on shares of EXAS given a handful of deep flaws used in the study." (9/10/2019)

Has EXACT Sciences been receiving favorable news coverage?

Headlines about EXAS stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. EXACT Sciences earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about EXACT Sciences
.

Are investors shorting EXACT Sciences?

EXACT Sciences saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 14,328,900 shares, a decline of 9.4% from the February 27th total of 15,820,000 shares. Based on an average daily volume of 3,461,100 shares, the short-interest ratio is currently 4.1 days.
View EXACT Sciences' Short Interest
.

Who are some of EXACT Sciences' key competitors?

What other stocks do shareholders of EXACT Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), Paypal (PYPL), Advanced Micro Devices (AMD), Square (SQ), Aduro BioTech (ADRO) and AT&T (T).

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the following people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)
  • Mr. Graham P. Lidgard, Chief Science Officer (Age 70)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Mark Stenhouse, Pres of Cologuard (Age 52)

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.16%), Ensign Peak Advisors Inc (1.52%), Viking Global Investors LP (1.45%), William Blair Investment Management LLC (1.18%), Frontier Capital Management Co. LLC (1.10%) and Gilder Gagnon Howe & Co. LLC (0.94%). Company insiders that own EXACT Sciences stock include D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Michael S Wyzga and Scott C Johnson.
View institutional ownership trends for EXACT Sciences
.

Which major investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, Russell Investments Group Ltd., Viking Global Investors LP, Gilder Gagnon Howe & Co. LLC, KAMES CAPITAL plc, Victory Capital Management Inc., Hodges Capital Management Inc., and Canada Pension Plan Investment Board. Company insiders that have sold EXACT Sciences company stock in the last year include G Bradley Cole, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, and Scott C Johnson.
View insider buying and selling activity for EXACT Sciences
.

Which major investors are buying EXACT Sciences stock?

EXAS stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Cannell Peter B & Co. Inc., Frontier Capital Management Co. LLC, Point72 Asset Management L.P., First Trust Advisors LP, CWM LLC, Columbus Circle Investors, and Marsico Capital Management LLC.
View insider buying and selling activity for EXACT Sciences
.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $85.33.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $12.81 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. EXACT Sciences employs 4,110 workers across the globe.

What is EXACT Sciences' official website?

The official website for EXACT Sciences is www.exactsciences.com.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815.

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.